Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Today, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.

Prof. Pollard preparing to deliver coronavirus vaccinations at the Kassam Stadium © Oxford Health NHS Foundation Trust

The first such large scale centre to be set up by Oxford Health NHS Foundation Trust, the Kassam Stadium, home to the city’s League One football side, will be open to the public by invite-only, seven days a week, from 8am to 8pm, as part of the national effort to vaccinate against COVID-19.  

Prof. Pollard said:  

‘To see a vaccination centre in Oxford delivering the vaccine that was developed in the city is a great moment. So much hard work has gone into getting to this stage from the researchers developing the vaccine and the Oxford Health team making all the arrangements to set up and run an efficient vaccination centre. Many volunteers from Oxfordshire took part in the clinical trials and it is a huge credit to their commitment that we can benefit from this vaccine today. 

‘We anticipate that the vaccination of as many people as possible as soon as possible will start to have a big impact on hospitalisations and is something everyone has been hoping for. However, vaccination is only one part of the story - people should continue to follow public health measures, such as observing the rules of lockdown, social distancing, wearing masks and washing their hands until we get the virus back under control.’ 

Read the full story on the University of Oxford website

Similar stories

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.

Daily contact COVID-19 testing for students effective at controlling transmission in schools

A study by the University of Oxford has found that daily testing of secondary school students who were in contact with someone with COVID-19 was just as effective in controlling school transmission as the current 10-day contact isolation policy.